Posted by Michael Wonder on 03 Feb 2023
MHRA approves Rinvoq (upadacitinib monohydrate) as first oral advanced therapy to treat adults with moderately to severely active Crohn's disease
3 February 2023 - This approval for Great Britain marks the first marketing authorisation globally for the use of upadacitinib, a janus kinase inhibitor, in Crohn's disease. This follows upadacitinib's approval in ulcerative colitis last year.
AbbVie today announced that the UK MHRA has approved Rinvoq (upadacitinib monohydrate), a janus kinase inhibitor, for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biological agent.
